The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5740-5748

  Nikitenko, Leonid L ^a,b,c,f   Leek, Russell ^d   Henderson, Stephen ^a   Pillay, Nischalan ^a   Turley, Helen ^d   Generali, Daniele ^e,g   Gunningham, Sarah ^h   Morrin, Helen R ^h   Pellagatti, Andrea ^d   Rees, Margaret C P ^d   Harris, Adrian L ^e   Fox, Stephen B ^i,j  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KEBLE COLLEGE   (United Kingdom)

^c LINACRE COLLEGE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f SCIENTIFIC CENTRE FOR FAMILY HEALTH AND HUMAN REPRODUCTION PROBLEMS   (Russian Federation)

^g Centro di Medicina Molecolare   (Italy)

^h UNIVERSITY OF OTAGO   (New Zealand)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; CALCITONIN RECEPTOR LIKE RECEPTOR; MESSENGER RNA;

ADULT; ADVANCED CANCER; ARTICLE; AUTOCRINE EFFECT; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DNA HYBRIDIZATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TISSUE MICROARRAY; UPREGULATION;

ADRENOMEDULLIN; AGED; AUTOCRINE COMMUNICATION; CALCITONIN RECEPTOR-LIKE PROTEIN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; TUMOR BURDEN;

EID: 84886427983     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1712     Document Type: Article

References (49)

1. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192:553-60.
2. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138-67.
3. Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. Regul Pept 2003;112:175-83.
4. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006;94:1-7.
5. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
6. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor- like receptor. Nature 1998;393: 333-9.
7. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. Themammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002;54:233-46.
8. Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J Cell Sci 2003;116:4867-9.
9. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3:639-50.
10. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of betaarrestin-and G protein-biased agonists. Trends Mol Med 2011;17: 126-39.
11. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011;10:47-60.
12. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94.
13. Gentleman R. Bioinformatics and computational biology solutions using Rand Bioconductor. New York; Cambridge, MA: Springer; 2005.
14. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004;20:307-15.
15. Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S, et al. A molecular map of mesenchymal tumors. Genome Biol 2005;6: R76.
16. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004;36:687-93.
17. Nikitenko LL, Brown NS, Smith DM, MacKenzie IZ, Bicknell R, Rees MC. Differential and cell-specific expression of calcitonin receptor-like receptor and receptor activity modifying proteins in the human uterus. Mol Hum Reprod 2001;7:655-64.
18. Charlesworth PJ, Kilbey N, Taylor M, Leek R, Cranston D, Turner G, et al. Automated uro-oncology data collection: the Cancer Research Uro-Oncology Database. BJU Int 2010;105:1663-6.
19. Eble JN. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004.
20. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6: 655-63.
21. Hermanek P, Scheibe O, Spiessl B, Wagner G. [TNM classification of malignant tumors: the new 1987 edition]. Radiobiol Radiother 1987;28: 845-6.
22. Nikitenko LL, Blucher N, Fox SB, Bicknell R, Smith DM, Rees MC. Adrenomedullin and CGRP interact with endogenous calcitoninreceptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. J Cell Sci 2006;119:910-22.
23. Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 2009;100:405-11.
24. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Upregulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005;65:8690-7.
25. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:e45.
26. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol 2010;176:2019-28.
27. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999;79:991-5.
28. Hilairet S, Foord SM, Marshall FH, Bouvier M. Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins. J Biol Chem 2001;276:29575-81.
29. Nikitenko LL, Cross T, Campo L, Turley H, Leek R, Manek S, et al. Expression of terminally glycosylated calcitonin receptor-like receptor in uterine leiomyoma: endothelial phenotype and association with microvascular density. Clin Cancer Res 2006;12:5648-58.
30. Dawson C, Whitfield H. ABC of urology-urological malignancy .3. Renal and testicular carcinoma. Br Med J 1996;312:1146-8.
31. Godley PA, Stinchcombe TE. Renal cell carcinoma. Curr Opin Oncol 1999;11:213-7.
32. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, et al. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res 2007;13:667s-70s.
33. Jain RK. Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer. Nat Rev Cancer 2008;8:309-16.
34. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38.
35. Favaro JP, George DJ. Targeted therapy in renal cell carcinoma. Expert Opinion on Investigational Drugs 2005;14:1251-8.
36. Srinivasan R, Armstrong AJ, Dahut W, George DJ. Anti-angiogenic therapy in renal cell cancer. BJU International 2007;99:1296-300.
37. Wilkinson RN, Koudijs MJ, Patient RK, Ingham PW, Schulte-Merker S, van Eeden FJ. Hedgehog signaling via a calcitonin receptor-like receptor can induce arterial differentiation independently of VEGF signaling in zebrafish. Blood 2012;120:477-88.
38. Deville JL, Bartoli C, Berenguer C, Fernandez-Sauze S, Kaafarani I, Delfino C, et al. Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. Int J Cancer 2009;125:2307-15.
39. Fujita Y, Mimata H, Nasu N, Nomura T, Nomura Y, Nakagawa M. Involvement of adrenomedullin induced by hypoxia in angiogenesis in human renal cell carcinoma. Int J Urol 2002;9:285-95.
40. Michelsen J, Thiesson H, Walter S, Ottosen PD, Skott O, Jensen BL. Tissue expression and plasma levels of adrenomedullin in renal cancer patients. Clin Sci 2006;111:61-70.
41. Nouguerede E, Berenguer C, Garcia S, Bennani B, Delfino C, Nanni I, et al. Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo. Cancer Med 2013;2:196-207.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
43. Fritz-Six KL, Dunworth WP, Li M, Caron KM. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 2008;118:40-50.
44. Jin D, Harada K, Ohnishi S, Yamahara K, Kangawa K, Nagaya N. Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema. Cardiovasc Res 2008;80:339-45.
45. Maybin JA, Battersby S, Hirani N, Nikitenko LL, Critchley HO, Jabbour HN. The expression and regulation of adrenomedullin in the human endometrium: a candidate for endometrial repair. Endocrinology 2011;152:2845-56.
46. Nikitenko LL, Shimosawa T, Henderson S, Makinen T, Shimosawa H, Qureshi U, et al. Adrenomedullin haploinsufficiency predisposes to secondary lymphedema. J Invest Dermatol 2013;133:1768-76.
47. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467:543-9.
48. Kaafarani I, Fernandez-Sauze S, Berenguer C, Chinot O, Delfino C, Dussert C, et al. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J 2009;23:3424-35.
49. Archbold JK, Flanagan JU, Watkins HA, Gingell JJ, Hay DL. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol Sci 2011;32:591-600.